Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This updated guideline from the British Association of Dermatologists discusses current recommendations for managing alopecia areata but reports no new clinical research findings.

This review provides an overview of scalp psoriasis treatments but presents no new clinical results; it highlights various options including coal tar, salicylic acid, corticosteroids, and vitamin D3 analogues.

This review discusses current treatment challenges and strategies for managing psoriasis in the scalp, nails, and intertriginous areas, emphasizing the need for effective and well-tolerated long-term options, but reports no new clinical results.

This study found that alopecia in hereditary resistance to 1,25(OH)2D may indicate a more severe form of the condition, associated with earlier diagnosis and different responses to calciferol therapy.

This study suggests that there is a U-shaped relationship between vitamin D hormonal forms and aging, with an optimal serum calcidiol concentration needed to minimize aging-related chronic disease risk.

This study found that measuring 24-OHase induction by 1,25(OH)2D3 in cultured skin fibroblasts is a sensitive test for detecting genetic defects in the 1,25(OH)2D effector pathway.

This article discusses a new global consensus on the classification of vitiligo, describing histopathological findings and outlining treatment strategies, but reports no new clinical results.

Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.

Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.

This review discusses the various skin manifestations associated with end-stage renal disease and their potential causes but reports no new clinical findings; the authors emphasize pruritus as a significant condition.

These guidelines review the management of complications and specific forms of congenital ichthyosis and report no new results; they summarize expert and evidence-based recommendations for clinicians.

This review discusses the potential causes and treatments for frontal fibrosing alopecia but reports no new clinical findings, highlighting the need for further research to understand its pathogenesis and develop validated treatments.

This review discusses the dermatological adverse events from immunosuppressive and anti-TNF therapy in IBD, finding increased risks of non-melanoma skin cancer and other skin conditions, and recommends regular cancer screening.

This study found that cyclophosphamide induced significant keratinocyte apoptosis in anagen hair follicles of mice, while topical calcitriol-analogs reduced this apoptosis, suggesting a protective effect against chemotherapy-induced alopecia.

This study found no protective effect of topical calcipotriol on hair loss in chemotherapy patients, and the authors propose the term "atrophic telogen effluvium" for this type of hair loss.

This article reviews the process of repigmentation in vitiligo and emphasizes the role of UV light as the most potent stimulus, with no new clinical findings reported.

This review highlights that scalp pruritus is a complex condition with various underlying causes, making it a challenge to diagnose and manage effectively. It emphasizes the need for comprehensive patient evaluation, history-taking, and personalized treatment strategies to address quality of life impacts.

This article discusses central centrifugal cicatricial alopecia, highlighting its prevalence, potential genetic factors, and management challenges, but reports no new clinical conclusions and calls for further research.

This article reviews the use of cyclosporine in dermatological conditions, noting its benefits in treating various skin diseases despite known adverse effects like nephrotoxicity and hypertension, and highlights its preferred use over other immunosuppressants due to an early therapeutic response and a good safety profile.

This article reviews clinical and histopathological aspects of cutaneous lupus erythematosus and its treatment, emphasizing the importance of photoprotection and outlining current therapies, but reports no new experimental results.

This study found that pentoxifylline plus topical corticosteroids had the highest treatment success rate for alopecia areata compared to no treatment, but the best overall treatment remains uncertain due to varying data.

This review discusses the potential benefits of nonantibiotic macrolides for treating inflammatory skin disorders and reports no new clinical results.

In this case report, etanercept was observed to effectively resolve symptoms of refractory acrodermatitis continua suppurativa Hallopeau after previous treatments had limited success.

This article discusses recent advancements in treatments for psoriasis, including new drug approvals and innovative therapeutic approaches, but reports no new clinical results.

This review discusses the progress in research on topical formulations for treating alopecia, highlighting potential advantages of advanced formulation technologies but reporting no new clinical results.

This study found that xerosis and pruritus are prevalent in patients with chronic renal failure undergoing hemodialysis, highlighting the importance of early recognition of skin issues to alleviate discomfort and reduce complications.

This review highlights current treatment options for frontal fibrosing alopecia, noting that 5-α-reductase inhibitors, intralesional steroids, and hydroxychloroquine have the highest evidence of effectiveness, while other therapies show variable results and need further research.

This review examines the potential roles of vitamin D in the pathogenesis of alopecia areata and suggests that vitamin D analogs like calcipotriol may have therapeutic potential.

This review discusses erosive pustular dermatosis of the scalp, highlighting its wide variety of causes and multiple effective treatment options beyond high-potency topical steroids, and reports no new clinical results.

This meeting report provides an overview of recent evidence on vitiligo treatments, indicating a lack of standardized outcome measures and emphasizing the need for more consistent clinical trials.